Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047294 · ClinicalTrials.gov registry record · Phase 2
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00047294: Completed Phase 2 study, sponsored by Dana-Farber Cancer Institute.
NCT00047294 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00047294, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor and may increase the effectiveness of temozolomide by making tumor cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of combining temozolomide, thalidomide, and celecoxib following radiation therapy in treating patients who have newly diagnosed glioblastoma multiforme.
Interventions
- DRUG temozolomide
- PROCEDURE adjuvant therapy
- DRUG thalidomide
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-04 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
What the finished NCT00047294 record still lists
NCT00047294 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which temozolomide is the first listed.
NCT00047294 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00047294 about?
NCT00047294 is a clinical study titled "Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor and may increase the effectiveness of temozolomide by making tumor cells more sensi...
What is the current status of trial NCT00047294?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-04. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00047294?
The interventions under investigation include: temozolomide (DRUG), adjuvant therapy (PROCEDURE), thalidomide (DRUG), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00047294?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia